OKYO: OKYO Pharma Ltd insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Clinical trial readouts
1 Phase 2 or 3 trials by OKYO Pharma Ltd with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-05 (est.) | Urcosimod ophthalmic solution is a preservative-free topical | Neuropathic Corneal Pain | Phase 3 | 111 | Not yet recruiting | NCT07838506 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.